Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25493196 | 0.82 | PDE2A (0.40) | PDE2A | |
| SCHEMBL17289144 | 0.81 | PNMT (0.40) | PDE2A | |
| SCHEMBL24305261 | 0.77 | CA12 (0.41) | PDE2A | |
| SCHEMBL17288959 | 0.74 | PNMT (0.40) | PDE2A | |
| SCHEMBL17288604 | 0.71 | METAP1 (0.36) | — | |
| SCHEMBL1855767 | 0.69 | ALDH1A1 (0.41) | — | |
| SCHEMBL17288853 | 0.67 | DRD2 (0.44) | — | |
| SCHEMBL8806121 | 0.67 | PARP1 (0.35) | — | |
| SCHEMBL25273345 | 0.67 | ASIC3 (0.51) | — | |
| SCHEMBL3592871 | 0.67 | PDE2A (0.32) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662811-B2 | N-(((5R)-5-((1-methylethyl)amino)-5,6,7,8-tetrahydro-2-naphthalenyl)methyl)-2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-1,2,3,4-tetrahydro-2-pyrazinyl)acetamide; for treatment of pain and diseases, such as inflammation mediated diseases | AMGEN INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | disclosed |
| US-7393852-B2 | Piperazine derivatives and methods of use | AMGEN INC. (US) | 2008-07-01 | — | — | US | disclosed |
| EP-1656355-B1 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1878728-A2 | Derivatives of piperazine and higher homologues thereof for the treatment of inflammation-related disorders | Amgen Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7199244-B2 | Cyclic amine derivatives and methods of use | AMGEN (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1656355-A2 | PIPERAZINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AMGEN INC. | 2006-02-02 | — | — | US | disclosed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005061467-A2 | PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | AMGEN INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100213-A1 | Triazoles and methods of use | CYP3A5, CYP3A43, CYP2E1 | PDE2A 587/4885 |
| US-20060025400-A1 | 1,2,3,4-Tetrahydropyrazin-2-yl acetamides and methods of use | AADAC, PTGES2, LTC4S | PDE2A 361/4885 |
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | PDE2A 245/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | PDE2A 10/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | PDE2A 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.